The catalyst

Imported generic drugs can enter the United States tariff-free for two more years. After that, President Donald Trump has said non-US production will face a 100% tariff, potentially doubling a year later. India sends more than a third of its pharmaceutical exports to the US, with $9.7 billion at stake. The levy is not an earnings charge today; it is a deadline attached to factories, regulatory approvals and products whose selling prices are already kept low by generic competition.News sourcesjapantimes.co.jpThe Economic TimesThe Hindu

A tariff of that size cannot simply be absorbed by a low-margin supplier; Dr. Reddy’s chief executive has said US medicine prices would rise by roughly the tariff’s magnitude. Yet moving production is not like redirecting a shipment. A drug may need a new site, validation batches, customer consent and regulatory clearance before commercial supply can switch. The useful company question is therefore not who exports medicines, but whose existing economics and manufacturing position give it a credible choice before the clock expires.News sourcescnbc.comchannelnewsasia.com

In brief

What matters

  • The clockThe two-year exemption delays the levy but brings forward decisions on US manufacturing, site transfers, customer pricing and product exits.
  • The upstream testSMS Pharmaceuticals already earns 26% of revenue from North America and sells APIs rather than finished doses, so customer sourcing decisions matter alongside the tariff’s final scope.
  • The thin cushionIndoco has fresh US approvals for two liquid oral products but reported a latest-year loss and higher interest costs, making capital-heavy adaptation harder.
  • The future entrantOrchid plans five or six US sterile finished-dose launches by 2030; the tariff timetable could alter the economics before that strategy fully arrives.

Company landscape

How the catalyst reaches listed businesses

Discovery question
Which Indian-listed pharmaceutical companies below ₹5,000 crore have direct US generic-drug or API exposure, and how do their manufacturing position, margins and current investment plans change the tariff risk?
Nearer exposureBusinesses with a closer operating link
SMS Pharmaceuticals LtdSMSPHARMACore — established API exporter
Indoco Remedies LtdINDOCOCore — US ANDA formulation developer
Orchid Pharma LtdORCHPHARMACore — forward-integrating antibiotic producer

The tariff reaches through the formulation

Generic-drug economics are split across a chain. An API producer makes the active ingredient; a formulator turns it into a tablet, capsule or sterile dose; the finished product then carries an approved manufacturing site into the US market. A tariff on non-US manufacture can therefore reach an Indian company directly through its own shipment or indirectly when a downstream customer changes suppliers, production location or product economics. The final rules will decide how APIs and intermediate steps are treated, but no manufacturer can assume that an upstream position makes it invisible.News sourceschannelnewsasia.comThe Hindu

SMS Pharmaceuticals makes that upstream exposure concrete. It manufactures more than 55 APIs across 14 therapeutic segments, has filed over 120 drug master files and reported 88% of revenue from regulated markets. North America supplied 26% of its geographic revenue mix, while exports account for about 70–75% of sales. Its vertical integration and low dependence on Chinese raw materials may protect gross margin, but they do not answer whether US customers will keep buying an Indian-made API once their own finished-dose economics change. The first signal will be customer behaviour, especially because one buyer already contributes 28% of revenue.

Existing sales and future entry carry different risks

Indoco Remedies sits further downstream. It develops and manufactures finished dosage forms and runs an ANDA-led US business; in May it disclosed approvals for Brivaracetam and Lacosamide liquid orals. Those approvals create products that can be sold, but they also bind commercial supply to approved manufacturing arrangements. Indoco enters this policy window after reporting a latest-year net loss, debt-to-equity of 1.11 and higher interest costs from a foreign-currency loan. Management is already trying to reduce borrowings. A new US factory or an expensive site-transfer programme would therefore compete with balance-sheet repair, while abandoning products would waste approvals that took time and money to secure.

Orchid Pharma faces the reverse timing problem. About 95% of its revenue comes from cephalosporin APIs, while its stated growth plan moves both backwards into the key input 7-ACA and forwards into sterile finished doses for the US. The 1,000-tonne 7-ACA project carries ₹750 crore of capital expenditure and is scheduled for commissioning in FY27; five or six US sterile products are planned by 2030. Orchid’s latest evidence also says 30–40% of raw material is imported, with 7-ACA the largest item. Backward integration could improve supply control, but it consumes capital before the US formulation strategy is proven—and the tariff is meant to begin before the 2030 launch plan is complete.

August 2028 is an operating milestone

These companies are not one tariff trade. SMS has established North American API revenue and must watch what customers do. Indoco owns finished-dose approvals but has limited financial room for a second manufacturing base. Orchid is spending heavily on an integrated antibiotic chain while its US finished-dose business is still prospective. The same policy could shrink an order book, strand an approval or redirect a capital programme. It could also be renegotiated before any of those outcomes occur.News sourceThe Economic Times

The evidence worth following begins well before a tariff invoice appears. Watch for US manufacturing partnerships, named site transfers, approval amendments, customer renegotiations and discontinued low-volume products. For SMS, add North American share and customer concentration. For Indoco, compare new US launches with debt and interest expense. For Orchid, track 7-ACA commissioning separately from sterile-product approvals. If those disclosures remain unchanged through 2027, the grace period is being consumed rather than used.

Questions for the next filing

What would prove the connection?

  1. 1

    Which companies already sell APIs or finished generic drugs into North America?

  2. 2

    Where does each company sit between raw material, API and finished dosage, and what can it realistically relocate or reprice?

  3. 3

    Which regulatory, capacity, portfolio and margin disclosures would show that management is adapting before August 2028?

Risks and limits

What could break the argument?

  • The tariff rate, product coverage or implementation date could change through negotiation or later policy action before August 2028.
  • The US may be unable to replace low-cost generic supply quickly, leading buyers or policymakers to absorb, pass through or soften the levy rather than force wholesale relocation.
  • Company outcomes may be driven more by launches, regulatory compliance, customer concentration, financing and raw-material costs than by a tariff that remains two years away.

Keep following the thread

What we would check next

  • The final US rule’s treatment of APIs, finished doses and approved non-US manufacturing sites.
  • SMS Pharmaceuticals’ North American revenue share and largest-customer concentration.
  • Indoco’s US liquid-oral launches, borrowings and interest expense.
  • Orchid’s 7-ACA commissioning and dated US sterile-product approvals.
  • Any disclosed US partnerships, site transfers, approval amendments, repricing or product exits before August 2028.

Have a catalyst or business question of your own?

Use CompanySweeper to find the companies behind it.

Try this question free →
Research basis · 13 records reviewed

The narrative was checked against 8 company records and 5 topical sources. News links also appear beside the paragraphs that rely on them.

Research for idea discovery, not a recommendation to buy or sell securities.